Han Biomedical, Inc.
TTPEX:699927.50
TWD
+0.50
(+1.85%)
ISIN
TW0006999006
Return %
Stock
S&P 500
1Y
-21.96
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
TWD
•
in mil. unless spec.Working Capital
TWD
•
in mil. unless spec.Growth Rates
TWD
•
in mil. unless spec.Semi-annual Revenue
TWD
•
in mil. unless spec.Semi-annual Earnings Per Share
TWD
•
in mil. unless spec.Semi-annual Dividends Per Share
TWD
•
in mil. unless spec.Company Description
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- New Taipei Taiwan
- IPO Date
- Jul 31, 2024
- Website
- hanbiomedical.com
- Similar Companies
- Business
- Han Biomedical, Inc. is a Taiwan-based biotechnology and medical device company that specializes in the research, design, development, and commercialization of advanced biomaterials for structural tissue repair, wound care, and surgical reconstruction. Founded in 2009 and headquartered in New Taipei City, Taiwan, the company leverages proprietary biomaterial purification and formulation platforms based on natural biopolymers, primarily medical-grade collagen and sodium hyaluronate, to engineer specialized medical devices across surgical, gynecological, orthopedic, urological, and dermatological specialties. The company's core product portfolio comprises: BarriGel, an absorbable anti-adhesion hydrogel formulated with high-purity hyaluronic acid designed to prevent or reduce post-operative tissue fibrosis and adhesions in tendon, joint, peripheral nerve, and general surgical procedures; Hancare collagen dressings, developed as biocompatible structural scaffolds to promote cellular migration and tissue regeneration in acute trauma and chronic non-healing wounds; patent-protected collagen-infused non-adherent gauze for specialized surgical dressing applications; HanBio Patient Lubricant, an aqueous mucosal moisturizing gel indicated for the relief and management of genitourinary symptoms in peri-menopausal and post-menopausal women; and therapeutic bladder instillation solutions formulated for mucosal barrier replenishment in interstitial cystitis and chronic inflammatory bladder disorders. Han Biomedical markets and distributes its medical products to public medical centers, private hospital networks, and surgical clinics throughout Taiwan, while actively pursuing international distribution across East Asia, Southeast Asia, and Europe. In recent developments, Han Biomedical listed its shares on the Taipei Exchange (TPEx) Emerging Stock Board under ticker 6999 on July 31, 2024. To accelerate its international commercial expansion and clinical adoption in Western markets, the company established a wholly owned European subsidiary, Han Biomedical GmbH, located at the BioCity Campus in Leipzig, Germany, and was selected for the Medical Forge accelerator program organized by biosaxony to support European regulatory pathways, clinical integration, and market penetration across Germany and the European Union.